Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.

The mean duration of exposure to semaglutide or placebo in the overall trial population was 34.2±13.7 months (33.3±14.4 months for semaglutide and 35.1±13.0 months for placebo); patients ...

Woman shares journey of weight loss and gain after using semaglutide One woman shares how she lost 50 pounds using the popular medication to aid weight loss, including side effects and what ...

A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name Ozempic — may help reduce not only alcohol cravings, but the amount of ...

Semaglutide mimics a hormone called GLP-1 that’s usually released when the body detects carbohydrates, proteins, and other lipids after a meal. This sends a message to the brain that you’ve ...

Semaglutide was initiated at a dose of 0.25 mg once weekly, and the dose was increased every 4 weeks in accordance with recommended dosing (from 0.25 mg to 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg ...

Compounded semaglutide is a non-FDA-approved alternative to products that contain semaglutide, such as Ozempic. Learn how the safety and efficacy of compounded semaglutide compares with Ozempic.

Send comments and news tips to [email protected]. Cite this: Semaglutide Improves Knee Osteoarthritis Pain, Physical Function in Phase 3 Trial - Medscape - April 23, 2024.